Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bangkok Genomics Innovation PCLBKK:BKGI +0.94%45 Return-on-Tangible-Asset is 16.08% as of Dec. 2025, which is 17% above its 10-year median of 13.71. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks better than 75.12% on this metric.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's Return-on-Tangible-Asset or its related term are showing as below:
BKK:BKGI'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 7.05 Med: 13.71 Max: 74.11
Current: 7.3
During the past 7 years, Bangkok Genomics Innovation PCL's highest Return-on-Tangible-Asset was 74.11%. The lowest was 7.05%. And the median was 13.71%.
BKK:BKGI's Return-on-Tangible-Asset is ranked better than 75.12% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.64
vs BKK:BKGI: 7.30
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Bangkok Genomics Innovation PCL Return-on-Tangible-Asset Related Terms
Bangkok Genomics Innovation PCL Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BKGI vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 16.08% mean?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a Return-on-Tangible-Asset of 16.08% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bangkok Genomics Innovation PCL and its competitors. This is 17% above median its historical median of 13.71. Over the past decade, Bangkok Genomics Innovation PCL's Return-on-Tangible-Asset has ranged from 7.05 to 74.11. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #53 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 24.9%.
Is Bangkok Genomics Innovation PCL's Return-on-Tangible-Asset too high?
Bangkok Genomics Innovation PCL's current Return-on-Tangible-Asset of 16.08% is 17% above median its 10-year median of 13.71. Over the past 10 years, this metric has ranged from a low of 7.05 to a high of 74.11. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #53 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #53 out of 213 companies for Return-on-Tangible-Asset. This places Bangkok Genomics Innovation PCL in the top 25% of its industry — outperforming the majority of peers. Historically, Bangkok Genomics Innovation PCL's own Return-on-Tangible-Asset has ranged from 7.05 to 74.11 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bangkok Genomics Innovation PCL and its competitors. Bangkok Genomics Innovation PCL's current Return-on-Tangible-Asset is 16.08%, which is 17% above median its own 10-year median of 13.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current Return-on-Tangible-Asset of 16.08%. The current Return-on-Tangible-Asset is 16.08%, which is 17% above median its 10-year median of 13.71. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current Return-on-Tangible-Asset is 16.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
